MIRM Stock Forecast & Price Target

Mirum Pharmaceuticals has demonstrated strong financial momentum, with Livmarli net sales revenue reaching $64.1 million in the fourth quarter of 2024, marking an 8.4% quarterly growth and a remarkable 54.5% increase year-over-year. The projections for continued revenue growth are bolstered by anticipated contributions from Livmarli's indications, as well as an expanding bile acid product portfolio that recently gained FDA approval to treat cerebrotendinous xanthomatosis. Additionally, encouraging clinical data for volixibat suggests significant improvements for treated patients, positioning Mirum as a cash-flow positive, commercially viable entity with multiple upcoming clinical milestones.

Mirum Pharmaceuticals is facing significant financial challenges, evidenced by a reported FY2024 net loss of $87.9 million and considerable operating expenses totaling $424.8 million, comprised of R&D, SG&A, and cost of goods sold. The company's prospects are further hindered by risks related to sales growth for its products Livmarli and volixibat, potential regulatory hurdles, and the necessity to differentiate its pipeline from competitors to ensure commercial uptake. Furthermore, the continuous net losses may force the company to seek additional funding, which poses a risk of dilution for existing shareholders and could further delay the path to profitability amidst potential operational challenges.